Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


SpyGlass observes $27.5m
The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.
Lexeo stacks up $85m
Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.
LifeMine Therapeutics lands $50m
LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.
Daily deal net: January 12, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Neural Galaxy detects pre-series A cash
The brain disease treatment developer was founded in 2019 on the back of more than a decade’s collaborative research from MIT and Harvard.
Carisma motivates investors for $47m series B
IP Group was among the investors for UPenn-founded cancer immunotherapy developer Carisma Therapeutics, which has now raised nearly $109m altogether.
Werewolf wins over UPMC for series B
UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.
Dice Molecules determines series C investors
Osage University Partners has contributed to an $80m round for Dice Molecules, which is advancing Stanford University research and is also backed by Sanofi and Alexandria.

Other News

Daily deal net: January 8, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Neuros Medical implants $38.5m
CWRU‘s pain neurostimulation spinout has secured series BB funding ahead of a 180-patient trial.
Investors hook up Hinge Health with $300m
IP Group portfolio company Hinge Health has pushed its valuation to $3bn following a $300m series D round co-led by Coatue Management and Tiger Global.
AMP Robotics accesses $55m in series B
UC-backed Congruent Ventures has contributed to a $55m round that will support the recycling robot maker's expansion plans.
The Engine helps pour $50m into Boston Metal
Boston Metal is most of the way to a $60m target for its latest round, thanks to a consortium that included returning backer The Engine.
Oxbotica takes series B for a $47m spin
University of Oxford’s autonomous driving software developer Oxbotica has secured $47m in a series B round featuring IP Group as well as several corporates.

Editor's Picks

Investment Unit of the Year: Cambridge Enterprise Seed Funds
With hundreds of university venture funds, internal commercialisation vehicles and third-party firms the reality in today’s innovation ecosystem, selecting the nominees and the winner for Investment Unit of the Year is increasingly challenging.
Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
test reg